NeurogesX, chronic pain treatment co., files for $69M IPO
Updated
NeurogesX, a San Carlos drug company developing treatments for chronic pain, has filed for an initial public offering to raise $69 million.
NeurogesX has raised about $95 million from venture firms, including Alta Partners, Arch Venture Partners, Montreux Equity Partners and Walden International.
Next Story: Accuray, robotic-surgery system, prices IPO at $18 per share
Previous Story: Veraz, a VoIP equipment provider, raises $10M more before IPO
